These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32035014)

  • 1. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
    Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
    AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
    Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
    Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
    Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
    Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.
    Kumagai Y; Fujita T; Maeda M; Sasaki Y; Nagaoka M; Huang J; Takenaka T; Kawai M
    J Clin Pharmacol; 2020 Jun; 60(6):702-710. PubMed ID: 32026490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
    Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
    J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.
    Chen J; Li J; Wu J; Song Y; Li L; Zhang J; Dong R
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1252. PubMed ID: 39073244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
    Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects.
    Zenklusen I; Dingemanse J; Reh C; Gehin M; Kaufmann P
    Drugs R D; 2024 Mar; 24(1):97-108. PubMed ID: 38472696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
    Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
    Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
    Toyama K; Furuie H; Kuroda K; Ishizuka T; Okuda Y; Shimizu T; Kato M; Igawa Y; Nishikawa Y; Ishizuka H
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):685-694. PubMed ID: 34383278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
    Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
    Berger B; Kaufmann P; Berse M; Treiber A; Grignaschi N; Dingemanse J
    Pharmacol Res Perspect; 2023 Oct; 11(5):e01143. PubMed ID: 37800597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.
    Wiebe ST; Meid AD; Mikus G
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):527-542. PubMed ID: 32772302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
    J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
    Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
    Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.